Four-week Study of the Safety and Efficacy of NLS-2 (Mazindol Extended Release) in the Treatment of Narcolepsy
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult
patients with narcolepsy. The study will enroll approximately 60 patients and eligible
patients will be treated to receive either NLS-2 or placebo for 4-weeks.